에서 실시간으로 운영 중이에요!
자세히 알아보기
Lite Strategy Inc
LITS
LITS
소개: Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients. The company operates in the segments: Digital Asset Treasury Strategy and Development of Pharmaceutical Products.
직원 수: 5
뉴스
긍정적
중립
부정적
투자 심리
3개월
긍정적
0%
중립
100%
부정적
0%
Lightweight Charts™를 사용해 가격 차트를 구현했어요.